JPRN-UMIN000035555招募中未知
Efficacy and Safety of SGLT2 Inhibitor Ipragliflozin in with Type 1 Diabetes patients using FGM - Efficacy and Safety of SGLT2 Inhibitor Ipragliflozin in with Type 1 Diabetes patients using FGM
Minami Osaka Hospital Internal Medicine0 个研究点目标入组 20 人开始时间: 2019年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.The patient with severe ketosis, diabetic comA or previous coma within six weeks before examination start 2.The patient who developed severe hypoglycemia (a diabetic coma or a previous coma and convulsionsneed the assistance of the third person) within six weeks before examination start 3.The patient with medically important renal disease such as a history of renal vascular occlusive disease, nephrectomy, kidney transplantations, etc 4.The patient with dysuria, anuria, oliguria or the symptom of the anuria 5.The patient whom urinary tract infection having subjective symptoms, a sexual organs infectious disease developed in within six weeks before examination start 6.The patient with a severe renal function disorder (eGFR <30mL/min/1.73m2 or serum creatinine level >= 2.0mg/dL) or the end-stage renal disease on dialysis 7.The patient with a proliferative retinopathy (however, patients symptoms are stable by implementing the photocoagulation, etc., can incorporate) 8.The patient complicated with serious digestive tract disturbance within two weeks before examination start or the patient who has an operation career of serious digestive tract disturbance 9.The patient with pregnancy or may be pregnant and the patient in nursing 10.The patient with severe infectious disease, serious injury and before and after operation 11.The patient who receives systemic administration of corticosteroids drugs 12.The patient with a serious liver function disorder more than 100 U/l of AST or ALT 13.The patient with a history of allergy to Ipragliflozin 14.The patient with the past of a malignant tumor or the malignant tumor at the moment 15.In addition, patients who test the attending physician has determined to be inappropriate as a subject
研究者
相似试验
尚未招募
不适用
Efficacy and safety of SGLT2 inhibitor, Ipragliflozin in type 2 diabetes patients.Type 2 diabetes mellitusJPRN-UMIN000013898Chubu-Rosai Hospital Department of Diabetes and Endocrinology15
已完成
不适用
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetesJPRN-UMIN000016306Tokyo Medical and Dental University50
已完成
不适用
ong-term efficacy and safety of the SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus.JPRN-UMIN000037872akakinen Clinic630
尚未招募
不适用
Efficacy and Safety of Ipragliflozin, a selective SGLT2 inhibitor, in type 2 diabetes patients with insulin therapytype 2 diabetesJPRN-UMIN000014968Tokyo Medical University Hospital Division of Diabetes,Metabolism and Endocrinology50
招募中
不适用
Efficacy and Safety of SGLT2 inhibitors in patients with type 1 diabete.type 1 diabetesJPRN-UMIN000044317Hokkaido University Hospital200